Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$3.11 -0.2%	$2.98	$1.05 ▼ $3.97	$349.87M	1.92	713,444 shs	464,616 shs
CAPR Capricor Therapeutics	$7.01 -2.2%	$8.67	$3.98 ▼ $23.40	$327.79M	0.59	1.79 million shs	1.03 million shs
EPIX ESSA Pharma	$1.92 -0.5%	$1.82	$1.40 ▼ $7.88	$91.31M	1.55	317,193 shs	419,948 shs
ZYBT Zhengye Biotechnology	$6.70 -29.4%	$6.47	$3.50 ▼ $14.30	$447.61M	N/A	109,883 shs	566,512 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	-0.32%	+0.49%	-1.11%	+40.94%	+8.95%
CAPR Capricor Therapeutics	-6.52%	-13.61%	+14.35%	-33.98%	+75.31%
EPIX ESSA Pharma	+1.05%	+0.52%	+3.21%	+16.27%	-63.79%
ZYBT Zhengye Biotechnology	+24.87%	+12.98%	+66.78%	-2.47%	+948,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	2.1567 of 5 stars	3.5	1.0	0.0	0.0	3.1	0.8	0.6
CAPR Capricor Therapeutics	3.0405 of 5 stars	4.6	2.0	0.0	0.0	2.1	0.8	0.6
EPIX ESSA Pharma	1.5899 of 5 stars	1.0	3.0	0.0	0.0	2.8	3.3	1.3
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$7.75	149.60% Upside
CAPR Capricor Therapeutics	3.11	Buy	$22.56	221.76% Upside
EPIX ESSA Pharma	2.00	Hold	$2.00	4.17% Upside
ZYBT Zhengye Biotechnology	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest EPIX, CAPR, ZYBT, and ADCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/14/2025	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/14/2025	CAPR Capricor Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$31.00 ➝ $12.00
7/11/2025	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00
7/11/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$77.00 ➝ $24.00
6/30/2025	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
6/26/2025	CAPR Capricor Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
6/25/2025	CAPR Capricor Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/25/2025	CAPR Capricor Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $29.00
6/24/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$77.00
6/23/2025	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$43.00 ➝ $22.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$70.84M	4.93	N/A	N/A	($1.77) per share	-1.75
CAPR Capricor Therapeutics	$22.27M	14.39	N/A	N/A	$2.30 per share	3.05
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$2.30 per share	N/A
ZYBT Zhengye Biotechnology	$186.36M	1.70	$0.09 per share	73.76	$1.02 per share	6.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$157.85M	-$1.57	N/A	N/A	N/A	-220.00%	N/A	-53.73%	11/6/2025 (Estimated)
CAPR Capricor Therapeutics	-$40.47M	-$1.64	N/A	N/A	N/A	-181.71%	-62.71%	-50.82%	N/A
EPIX ESSA Pharma	-$28.54M	-$0.56	N/A	N/A	N/A	N/A	-21.71%	-21.22%	N/A
ZYBT Zhengye Biotechnology	$1.55M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest EPIX, CAPR, ZYBT, and ADCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q3 2025	EPIX ESSA Pharma	-$0.17	-$0.09	+$0.08	-$0.09	N/A	N/A
8/12/2025	Q2 2025	ADCT ADC Therapeutics	-$0.36	-$0.50	-$0.14	-$0.50	$17.82 million	$18.84 million
8/11/2025	Q2 2025	CAPR Capricor Therapeutics	-$0.48	-$0.57	-$0.09	-$0.57	$2.60 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A

Latest EPIX, CAPR, ZYBT, and ADCT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/5/2025	EPIX ESSA Pharma	--	$1.69		8/25/2025	8/19/2025	8/22/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.93	4.66
CAPR Capricor Therapeutics	N/A	4.37	4.37
EPIX ESSA Pharma	N/A	69.06	69.06
ZYBT Zhengye Biotechnology	0.01	1.31	0.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
CAPR Capricor Therapeutics	21.68%
EPIX ESSA Pharma	75.12%
ZYBT Zhengye Biotechnology	N/A

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.40%
CAPR Capricor Therapeutics	10.50%
EPIX ESSA Pharma	15.50%
ZYBT Zhengye Biotechnology	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	112.50 million	106.42 million	Optionable
CAPR Capricor Therapeutics	101	45.72 million	40.92 million	Optionable
EPIX ESSA Pharma	50	47.31 million	39.98 million	Optionable
ZYBT Zhengye Biotechnology	278	47.17 million	N/A	N/A

EPIX, CAPR, ZYBT, and ADCT Headlines

Recent News About These Companies

Zhengye Biotechnology Holding Ltd trading halted, volatility trading pause

August 21 at 2:55 PM | msn.com

Zhengye Biotechnology (NASDAQ:ZYBT) Raised to Hold at Wall Street Zen

August 2, 2025 | marketbeat.com

ZYBT | Zhengye Biotechnology Holding Ltd. Company Profile & Executives ...

July 17, 2025 | wsj.com

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results | ZYBT Stock News

July 3, 2025 | gurufocus.com

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results

July 3, 2025 | prnewswire.com

ZYBT | Zhengye Biotechnology Holding Ltd. Stock Overview (U.S.: Nasdaq) - Barron's

July 2, 2025 | barrons.com

ZYBT - Zhengye Biotechnology Holding Ltd Chart - Morningstar

June 27, 2025 | morningstar.comM

Zhengye Biotechnology Holding Ltd

June 21, 2025 | morningstar.comM

ZYBT Zhengye Biotechnology Holding Limited

May 30, 2025 | seekingalpha.com

Zhengye Biotechnology faces NASDAQ compliance issue

May 24, 2025 | investing.com

Zhengye Biotechnology Holding Limited Receives NASDAQ Delinquency Letter for Non-Compliance with Listing Requirements

May 23, 2025 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F

May 23, 2025 | globenewswire.com

Should We Be Cautious About Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 6.9%?

April 7, 2025 | finance.yahoo.com

Zhengye Biotechnology Holding Ltd.

April 3, 2025 | wsj.com

Zhengye Biotechnology Holding Limited (ZYBT)

March 27, 2025 | finance.yahoo.com

Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option

January 14, 2025 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering

January 8, 2025 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering

January 6, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPIX, CAPR, ZYBT, and ADCT Company Descriptions

ADC Therapeutics NYSE:ADCT

$3.10 -0.01 (-0.16%)

Closing price 03:59 PM Eastern

Extended Trading

$2.90 -0.20 (-6.44%)

As of 07:37 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Capricor Therapeutics NASDAQ:CAPR

$7.01 -0.16 (-2.23%)

Closing price 04:00 PM Eastern

Extended Trading

$7.07 +0.06 (+0.87%)

As of 07:55 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

ESSA Pharma NASDAQ:EPIX

$1.92 -0.01 (-0.52%)

Closing price 04:00 PM Eastern

Extended Trading

$1.93 +0.01 (+0.47%)

As of 04:43 PM Eastern

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Zhengye Biotechnology NASDAQ:ZYBT

$6.70 -2.79 (-29.40%)

As of 04:00 PM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time